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Background: Mycoplasma pneumoniae is one of the causative organisms of community-acquired pneumonia which
is found commonly in younger patients. Extrapulmonary complications similar to autoimmune disease are caused
by M. pneumoniae following the initial infection. The mechanism and pathology of onset is not clear, but it is
considered that excessive host immunoreactions play a part in the onset of mycoplasmal pneumonia and its
extrapulmonary complications. In this study, we investigated the participation of the immune response, excluding
the participation of Th1 and Th2 which has previously been investigated.
Results: In this study, the host immune response of an antigen induced inflammation model using SPF mice
repeatedly sensitized with M. pneumoniae antigens was analyzed. The specificity of M. pneumoniae antigens in
the Th17 response of murine lymphocytes in vitro was also examined. Frequent and concentrated sensitization
induced exacerbation of lung inflammation immunologically and pathologically, and evoked intrapulmonary
IL-17A and IL-10 production. M. pneumoniae antigen stimulation induced proliferation of mouse lymphocytes
and caused production of IL-17A and IL-10. In addition, it was shown that IL-17A and IL-10 production was
increased in the presence of IL-6 and TGF-β1.
Conclusions: It was shown that M. pneumoniae antigens induced potent immunoreaction and enhanced the
Th17 cell response both in vivo and in vitro, and that both Treg and IL-10 are involved in the suppression of
IL-17A production. This raises the possibility that breakdown of the immune balance may be part of the process
leading to subsequent development of extrapulmonary mycoplasmal pneumonia.
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Mycoplasmas are the smallest bacteria capable of autono-
mous replication, and these microorganisms are unique in
that they lack a bacterial cell wall. M. pneumoniae is an
etiologic agent responsible for community-acquired
respiratory tract infections (primary atypical pneumonia,
PAP) mainly in school-age children and young adults.
M. pneumoniae can spread from person to person via
droplets, attaching to human airway epithelial cells via
the P1 protein, one of the tip components of an adherent
organ on the bacterial cell surface [1,2].
Recently, it has been reported that the community-
acquired respiratory distress syndrome toxin (CARDS Tx)
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unless otherwise stated.activity similar to Bordetella pertussis toxin is produced by
M. pneumoniae [3]. CARDS Tx was not secreted into the
culture supernatant, but localized to the cytoplasmic and
cell membranes, inducing vacuolating cytotoxicity. How-
ever, it is difficult to explain the pathogenic mechanisms
of mycoplasmal pneumonia in relation to M. pneumoniae
virulence factors. Clinical symptoms of mycoplasmal
pneumonia in early childhood are not marked and man-
ifestations of M. pneumoniae infection such as pneumo-
nia appear only in school-age or older children [4]. Severe
inflammatory responses in the lung are also not com-
monly observed in M. pneumoniae infected immuno-
compromised hosts [5]. According to the report by
Tanaka et al. [6], it was inferred that accumulation of
lymphocytes and monocytes activated by M. pneumoniae
infection in the bronchi and lung tissue leads to both
insufficiency of lymphocytes at the periphery and negative
conversion in the tuberculin test. Furthermore, it wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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extrapulmonary complications such as Guillain-Barré
syndrome, Stevens-Johnson syndrome, hepatitis, myocar-
ditis and arthritis were observed subsequent to M. pneu-
moniae infections [7-10]. Consequently, the participation
of the excessive host immune response is thought to be
involved in the severity of mycoplasmal pneumonia and
also the onset of complications [11,12].
In recent years, a third positive effector T cell subset
known as Th17 cells were characterized by abundant pro-
duction of IL-17 [13,14]. IL-17 is more important than
IFN-γ in onset and exacerbation of autoimmune diseases
such as collagen-induced arthritis (CIA) and experimental
allergic encephalitis (EAE), which are thought to be patho-
genetically induced by the Th1 immune response [15,16].
On the other hand, inducible regulatory T cells (iTreg)
such as Tr1 and Th3 have been reported to contribute to
the suppression of the hyperimmune response [17,18].
It was reported that the Th17 cells are induced by
segmented filamentous bacteria (SFB) which colonize
the intestinal tract [19]. However, the relationship of
Th17 cells with the pathogenic mechanisms of myco-
plasmal pneumonia and its extrapulmonary complications
are not clear. Treg has not previously been identified as
an inhibiting factor of the M. pneumoniae inflammatory
response.
We have previously reported that experimental pneu-
monia can be caused by intranasal inoculation of
M. pneumoniae soluble sonicated antigens to specific
pathogen-free (SPF) mice [20,21]. In the present study,
we prepared a M. pneumoniae antigen induced inflam-
mation model by use of SPF mice recurrently inocu-
lated with M. pneumoniae antigens and performed
pathological and immunological analyses to examine
the induction mechanisms of Th17 and Treg cells.
Additionally, we investigated the specificity of Th17 and
Treg cell inducibility with mouse lymphocytes in vitro by
using various bacterial antigens and immunoactivatory
components.
Methods
Bacterial strains and culture conditions
The reference strain M. pneumoniae M129, stocked at
the Department of Infectious Diseases, Kyorin University
School of Medicine was used in this study.
M. pneumoniae cells were cultured at 37°C under a
5% CO2 atmosphere for 7 days in PPLO broth (Oxoid,
Hampshire, UK) containing mycoplasma supplement-G
(Oxoid) for the preparation of soluble M. pneumoniae anti-
gens. Klebsiella pneumoniae (ATCC 13883; American Type
Culture Collection, Rockville, MD) and Streptococcus pneu-
moniae (ATCC 33400) were cultured at 37°C under aerobic
conditions for 18 hours in brain heart infusion broth (BHI;
Becton Dickinson, MD) (BD Difco Franklin Lakes, NJ).Experimental animals and breeding conditions
Specific pathogen-free (SPF) female BALB/cAJcl mice
(5 weeks of age for antigen induced inflammation
model, and 6 weeks of age for harvest of splenocytes)
were purchased from Clea Japan (Tokyo, Japan) and
bred in isolators.
Preparation of sonicated M. pneumoniae crude antigens
M. pneumoniae soluble antigens were prepared as pre-
viously described [20,21]. The cultured bacteria were
harvested and washed 5 times by centrifugation at
10000 × g for 20 min (M. pneumoniae) or 3000 × g for
15 min (K. pneumoniae and S. pneumoniae) in Hanks’
balanced salt solution (Gibco, New York, USA). The
cells were suspended in saline and sonicated 10 times
for 1 min per burst at output 7 (Sonifier 250, Branson
Ultrasonic Corporation, Danbury, CT, USA). The super-
natant was decanted after centrifugation at 10000 × g
for 5 min, and served as crude soluble antigen. The pro-
tein concentration of the suspension was measured
using the Bio-Rad Protein Assay (Hercules, CA, USA).
Inoculation and sensitization conditions
Animal experiments were approved by the Institutional
Animal Care and Use Committee of Kyorin University
School of Medicine (Approval No. 95, 95–1, 95–2).
Mice were anaesthetized intraperitoneally with 25 mg/kg
body weight of sodium pentobarbital (Dainippon Sumitomo
Pharma, Osaka, Japan). SPF mice in Group A were
intranasally inoculated once a week for 5 weeks with
sonicated crude antigens prepared from M. pneumoniae
strain M129 (1 mg protein/kg/5 times). The inoculated
protein doses were changed in Groups B and C. In Group
B, lower doses (0.1 mg/kg) of the antigen were inoculated
once a week at day 0, 7 and 14, and higher doses (1 mg/
kg) of the antigen were used for the last inoculation at day
28. In Group C, crude antigen (1 mg/kg) was inoculated at
day 0 and 28 only. Control mice in Group D were inocu-
lated with saline once a week for 5 weeks (n = 5 or 6 in
each group).
Pathological examination
Mice were sacrificed on the day after the last sensitization.
The intermediate and lower lobes of the right lungs of
the mice were fixed in 5% formalin. Sections of paraffin-
embedded tissues were stained with hematoxylin and
eosin and analyzed by light microscopy.
Intrapulmonary mRNA gene expression analysis
Total RNA was extracted from the upper lobe of the
right lungs of the mice using the QIAzol, QIAshredder and
RNeasy Mini spin column RNA isolation Kit (QIAGEN
GmbH, Hilden, Germany). cDNA was synthesized from
sample RNA using ReverTra Ace RT PCR Kit (TOYOBO
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formed with SYBR Green Premix Ex Taq (TaKaRa Bio
Inc., Shiga, Japan) by the ABI 7500 Fast Real-Time PCR
System (Applied Biosystems, Inc. Carlsbad, California, US)
as described previously [22-25] using specific primers for
individual genes. Fold changes of targeted genes of each
sample were relatively quantified using threshold cycle
(Ct) values and calculated using the ddCT method nor-
malizing B-actin or 18S RNA values.In vitro analysis for specificity of differentiation inducing
activity of Th17 cells by M. pneumoniae antigens
The spleens were removed from three mice for each
experiment. Lymphocytes were separated from the
spleens of BALB/c mice by Lympholyte M (Cedarlane
Laboratories Limited, Hornby, Ontario, Canada). Lym-
phocytes (8 × 104 cells/0.2 ml) were then incubated with
20 ng/ml of mouse IL-6 (R&D Systems, Minneapolis,
MN, USA) plus 2 ng/ml of human TGF-β1(R&D Sys-
tems) at 37°C under 5% CO2 for 4 days in RPMI 1640
medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal calf serum (FCS; Gibco), 10 μM 2-mercap
toethanol (MP Biomedicals, Fountain Parkway, Solon,
OH), 50 μg/ml gentamicin (Schering Plough, Osaka,
Japan) and 2.5 μg/ml amphotericin B (Bristol-Myers
Squibb, Tokyo, Japan) [26].
In addition, lymphocytes were stimulated with the
Dynabeads Mouse CD3/CD28 T Cell Expander (Invi-
trogen, Carlsbad, CA) during the incubation period.
The sonicated crude antigens from M. pneumoniae
strain M129, K. pneumoniae ATCC 13883, S. pneumoniae
ATCC 33400, lipopolysaccharide from Escherichia coli
O127:B7 (SIGMA-ALDRICH, St. Louis, MO, USA), and
zymosan A from Saccharomyces cerevisiae (SIGMA-
ALDRICH) were added to the culture. A culture with-
out the addition of IL-6, TGF-β1 or antigens was
included as control.
After 4-day culture, cell viability, based on mitochon-
drial succinic dehydrogenase activity was measured
using a Cell Counting Kit-8 (Dojindo Molecular Tech-
nologies, Inc., Kumamoto, Japan) consisting of a WST-8
assay (2-{2-methoxy-4-nitrophenyl}-3-{4-nitrophenyl}-5-
{2, 4-disulfophenyl}-2H-tetrazolium, monosodium salt).
Culture supernatants were also harvested and assayed
for cytokine activities by ELISA.Statistical analysis
Statistical evaluations were performed with Dunnett
multiple comparison statistical test and Student’s t-test
for comparisons between groups.
A value of p < 0.05 was considered to be statistically
significant. Data are expressed as the mean ± the stand-
ard deviation.Results
Histopathological analysis
High dose and frequent M. pneumoniae antigen sensi-
tization caused severe inflammatory changes including
neutrophil infiltration and bronchial wall thickening in
the lung tissues of Group A mice (Figure 1a). Low dose
and frequent sensitization also induced neutrophilic
infiltration in the lungs of the mice in Group B, but this
inflammation was milder than that in Group A (Figure 1b).
In Group C mice with high dose and infrequent sen-
sitization, the inflammatory levels differed according
to lung site and localized inflammation with neutrophil
infiltration was observed (Figure 1c). No inflammatory
cell infiltration was observed in any of the tissues in the
saline control Group D mice (Figure 1d). These results
demonstrated that high dose and frequent M. pneumoniae
antigen sensitization induce significant inflammation in
the lung.
Immunological analysis for intrapulmonary cytokine
protein quantification
In Group A mice, IL-17A levels in lung tissues were
markedly increased (Figure 2a). Sensitization by lower
doses of M. pneumoniae antigens also led to a rise in
IL-17A levels in Group B mice. However, no significant
changes were found in Group C mice. The levels of
intrapulmonary IFN-γ and IL-4 in all mice were un-
detectable by ELISA (data not shown).
Intrapulmonary IL-10 production was not detected in
control Group D mice, but sensitization with M. pneu-
moniae antigens induced the production of IL-10 in
Groups A, B and C (Figure 2b).
Statistically significant increases in IL-17A and IL-10
mRNA expression were shown to depend on frequency
of sensitization and concentration of M. pneumoniae
antigens used (Figure 2c,d). Relative quantification of
tumor necrosis factor (TNF)-α mRNA and Keratinocyte-
derived chemokine (KC) mRNA expression as an index
of lung inflammation is shown in Figure 3a and b.
Up-regulation of TNF-α mRNA and KC mRNA was
observed in Groups A, B and C mice as expected ac-
cording to histopathological findings. Forkhead box p3
(Foxp3) is a master regulator of CD4+CD25+ naturally
occurring regulatory T cells (nTreg). Foxp3 mRNA was
highly expressed in only Group A mice (Figure 3c). In
contrast, no significant effect of M. pneumoniae antigens
on TGF-β1 mRNA expression was observed in the lung
(Figure 3d).
In vitro analysis for specificity of differentiation inducing
activity of Th17 cells by M. pneumoniae antigens
Chronological cytokine production by M. pneumoniae
antigens was examined. Lymphocytes were cultured





Figure 1 Histopathology of the lung of BALB/c mice after intranasal sensitization with M. pneumoniae-sonicated antigens. The figure
shows hematoxylin and eosin staining of lung sections from mice repeatedly inoculated with M. pneumoniae antigens (day 29). Lung tissue
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Figure 2 Cytokine levels and relative quantification of cytokine mRNA levels in lung tissues of BALB/c mice. (a) IL-17A levels per gram of
lung tissue. (b) IL-10 levels per gram of lung tissue. (c) Relative quantification of IL-17A mRNA levels. (d) Relative quantification of IL-10 mRNA
levels. Black bars, Group A mice; Grey bars, Group B mice; hatched bars, Group C mice; white bars, Group D mice. *p < 0.05, inoculate vs. Group D
(control) by Dunnett multiple comparison statistical test, #p < 0.05 by Student’s t-test.
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Figure 3 Relative quantification of cytokine mRNA levels in lung tissues of BALB/c mice. (a) Relative quantification of TNF-α mRNA levels.
(b) Relative quantification of KC mRNA levels. (c) Relative quantification of Foxp3 mRNA levels. (d) Relative quantification of TGF-β1 mRNA levels.
Black bars, Group A mice; Grey bars, Group B mice; hatched bars, Group C mice; white bars, Group D mice. *p < 0.05, inoculate vs. Group D (control) by
Dunnett multiple comparison statistical test, #p < 0.05 by Student’s t-test.
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the culture media was elevated from day 1 to day 4 and
maintained at 600–700 pg/ml (Figure 4a). IL-10 produc-
tion induced by M. pneumoniae antigens was observed to
be maintained at 400–500 pg/ml (Figure 4b). In the saline
control, elevation of IL-17A and IL-10 concentrations was
up to 100 pg/ml at day 4 (Figure 4a,b).Effects of M. pneumoniae and other bacterial antigens on
lymphocyte growth
Without IL-6 and TGF-β1, only 50 μg protein/ml of M.
pneumoniae antigens promoted the proliferation of lym-
phocytes (Table 1). In the presence of IL-6 and TGF-β1,
proliferation of lymphocytes was increased by either 10
or 50 μg protein/ml of M. pneumoniae antigens, while
50 μg protein/ml of either S. pneumoniae or K. pneumoniae
sonicated antigens markedly decreased viable lymphocyte
count. Similarly, in the presence of IL-6 and TGF-β1, soni-
cated antigens of S. pneumoniae (10 and 50 μg protein/ml)
and K. pneumoniae (5, 10 and 50 μg protein/ml) reduced
the growth of lymphocytes (Table 1). In the absence of IL-6
and TGF-β1, growth of lymphocytes was not inhibited by
LPS. However in the presence of IL-6 and TGF-β1, high
concentrations (10 and 50 μg protein/ml) of LPS sup-
pressed the multiplication of lymphocytes (Table 1). On theother hand, zymosan A promoted the proliferation of lym-
phocytes with or without IL-6 and TGF-β1 (Table 1).
Effect of M. pneumoniae and other antigens on
lymphocyte IL-17A production
M. pneumoniae antigens promoted the production of
IL-17A. Furthermore, in the presence of IL-6 and TGF-
β1, IL-17A production by lymphocytes markedly in-
creased in an antigen concentration-dependent manner
(Figure 5a). IL-17A production by lymphocytes induced
by either S. pneumoniae, K. pneumoniae antigens or LPS
was increased only twice as much as control in the pres-
ence of IL-6 and TGF-β1 (Figure 5b,c,d). The addition
of 50 μg protein/ml of S. pneumoniae antigens and
50 μg/ml LPS could not induce the levels of IL-17A
compared to M. pneumoniae antigens (Figure 5b,d).
Moreover, very low levels of IL-17A production were
observed in the presence of 50 μg protein/ml of
K. pneumoniae sonicated antigens (Figure 5c) and IL-17A
production was not increased by zymosan A stimulation
at all (Figure 5e).
Effect of M. pneumoniae and other antigens on
lymphocyte IL-10 production
M. pneumoniae antigens promoted the production of














































Figure 4 Effects of M. pneumoniae antigens on cytokine
production by murine lymphocytes. Lymphocyte culture
supernatant concentrations of (a) IL-17A (pg/ml), (b) IL-10 (pg/ml).
Closed squares (■) show stimulation with 50 μg protein/ml of
M. pneumoniae antigen. Closed triangles (▲) show saline control.
*p < 0.05 vs. saline control by Student’s t-test.
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an antigen concentration-dependent manner (Figure 6a).
IL-10 production by lymphocytes induced by S. pneumo-
niae and K. pneumoniae antigens increased only twice as
much as control in the presence of IL-6 and TGF-β1
(Figure 6b,c). However, LPS did not induce significant
lymphocyte IL-10 production, even in the presence ofTable 1 Effects of microbial antigens on lymphocyte growth w
Antigen
IL-6(-), TGF-β1(-)a
0 μg/ml 50 μg/ml 0 μg/
M. pneumoniae M129 229.6±19.1b
S. pneumoniae ATCC 33400 18.4±1.2b
K. pneumonia ATCC 13883 111.7±13.0 6.8±4.2b 100.0±
LPS from E. coli 0127: B8 128.8± 6.1b
Zymosan A from S. cerevisiae 197.9±10.2b
aRelative ratio (%) of viable lymphocyte count with or without IL-6 (20 ng/ml) and T
ratio is the mean ± standard deviation (four or five samples per group) of the numb
bSignificantly different (p < 0.05) from value for cytokine (−), antigen 0 μg/ml by Stu
cSignificantly different (p < 0.05) from value for 20 ng/ml of IL-6 and 2 ng/ml of TGFIL-6 and TGF-β1 (Figure 6d). IL-10 production by
zymosan A induction was increased in the presence of
IL-6 and TGF-β1, though this was only approximately
50% of that observed in M. pneumoniae antigen exper-
iments (Figure 6e).
Discussion
The pathogenic mechanism by which the diverse extra-
pulmonary symptoms subsequent to mycoplasma in-
fection occur is thought to be possibly due to indirect
tissue injury caused by an overzealous host immune
response [11,12].
In this study we investigated the Th17 and Treg based
immune response to mycoplasmal diseases using IL-17A
and IL-10 as index markers. It was therefore suggested
that extrapulmonary complications subsequent to the
development of mycoplasmal pneumonia were due to
breakdown of the immune response.
Histological inflammation was induced in the murine
lung by nasal inoculation of M. pneumoniae antigens, and
the levels of inflammation correlated with sensitization
conditions in this in vivo study. Severe inflammation was
observed in the higher-dose and frequent sensitization
group (Group A). Moreover, mRNA expression of TNF-α
and KC proinflammatory cytokines supported the histo-
pathological findings. This in vivo analysis revealed
that M. pneumoniae antigens were also capable of in-
ducing chemokines in our antigen induced inflammation
model. Intrapulmonary concentrations of IL-17A in
BALB/c mice were increased in Group A and B which
were sensitized frequently or sensitized with higher
amounts of M. pneumoniae antigens. We inferred that
the positive effector T cell balance (Th1-Th2-Th17) of
the antigen induced inflammation model was a persist-
ent Th17 dominant condition, as intrapulmonary Th1
and Th2 cytokines IFN-γ and IL-4 were not detected
but high concentrations of IL-17A and high expression
levels of IL-17A mRNA were detected in the lung of
BALB/c mice. The immunological response causes mi-
gration and generation of neutrophils, which plays a
part not only in host defense from bacterial infectionith or without IL-6 and TGFβ1
IL-6(+), TGF-β1(+)a
ml 1 μg/ml 5 μg/ml 10 μg/ml 50 μg/ml
81.9±5.8 101.5±10.9 134.7±15.6c 147.8±6.3c
110.1±6.3 100.9±12.9 66.8±5.2c 22.3±2.4c
8.1 109.2±4.1c 44.3±1.2c 27.3±1.6c 6.1±0.7c
86.5±2.7c 89.4±8.1 81.2±5.0c 56.5±7.0c
104.5±10.1 114.8±9.6c 124.9±4.0c 159.1±5.4
GF-β1 (2 ng/ml) stimulated with M. pneumoniae and other antigens. Relative
er of viable lymphocytes at day 4.
dent’s t-test.
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Figure 5 Effects of M. pneumoniae and other antigens on IL-17A production in murine lymphocytes. IL-17A concentration (pg/ml) in the
culture supernatant of murine lymphocytes stimulated with antigens of: M. pneumoniae strain M129 (a), S. pneumoniae strain ATCC 33400 (b),
K. pneumoniae strain ATCC 13883 (c), LPS from E. coli O127:B8 (d), Zymosan A from S. cerevisiae (e). *p < 0.05 vs. TGF-β1 and IL-6 (+), Ag (−) by
Dunnett multiple comparison statistical test; #p < 0.05 vs. cytokine (−), Ag (−) by Student’s t-test.
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diseases such as chronic rheumatoid arthritis [27,28].
Our experimental results demonstrated that even re-
petitive sensitization with a small amount of M. pneu-
moniae antigens induced a Th17 dominant immune
response. This discovery raises the possibility that clin-
ically mild symptoms observed in mycoplasmal pneumo-
nia caused by a small bacterial colonization load may
still result in enhancement of the Th17 response, elicit-
ing host autoimmune diseases by persistent infection.
Therefore, it is not only simple infection but the antigen
inoculation conditions that are involved in the onset of
extrapulmonary complications resembling autoimmune
disease.It was recently reported that polysaccharide derived
from Bacteroides fragilis activated Treg cells and pro-
moted a production of IL-10 in the intestinal tract [29].
Both factors elevate the intrapulmonary concentration of
IL-10 and up regulate IL-10 mRNA expression in the
lungs of BALB/c mice representing persistent IL-10 pro-
duction in this M. pneumoniae antigen induced inflam-
mation model.
It was previously reported that IL-10 deficient mice
developed spontaneous enterocolitis similar to human
inflammatory bowel disease [30], and it was proven
that large quantities of IL-10 improved formalin or
dextran sulfate sodium (DSS) induced colitis [31,32].
















0     50      0      1       5     10     50  (ug/ml)
IL-6, TGF-β1 (+)
0     50      0      1       5     10     50  0     50      0      1       5     10     50  
0     50      0      1       5     10     50  



























(a) (b)      
(c)      (d)      





















































Figure 6 Effects of M. pneumoniae and other antigens on IL-10 production in murine lymphocytes. IL-10 concentration (pg/ml) in the
culture supernatant of murine lymphocytes stimulated with antigens of M. pneumoniae strain M129 (a), S. pneumoniae strain ATCC 33400
(b), K. pneumoniae strain ATCC 13883 (c), LPS from E. coli O127:B8, (d), Zymosan A from S. cerevisiae (e). *p < 0.05 vs. TGF-β1 and IL-6 (+),
Ag (−) by Dunnett multiple comparison statistical test; #p < 0.05 vs. cytokine (−), Ag (−) by Student’s t-test.
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strated previously. Thus when IL-10 production is de-
creased by inhibition of Tr1 differentiation, lung
inflammation induced by M. pneumoniae antigens can-
not be mitigated, and extrapulmonary complications
similar to autoimmune diseases may also occur in vivo.
These results suggest that inflammation induced by IL-
17A production in Th17 cells is mitigated by Tr1 pro-
duction of IL-10.
We could not confirm the inhibitory effect of Th3
cells on immune responses at inflammatory sites, as
TGF-β1 mRNA expression did not correlate with the
frequency of sensitization or dose in this antigen in-
duced inflammation model.CD4+CD25+T cells express cytotoxic T-lymphocyte
antigen 4 (CTLA-4) with membrane-associated TGF-β
on the cell surface, which suppresses multiplication of
positive effector T cells by direct cytoadherence [33,34].
Foxp3, a master regulatory gene is constitutively expressed
in CD4+CD25+T cells [35], and both Tr1 and Th3 cells are
negative for Foxp3 [36,37]. It was assumed that intra-
pulmonary Foxp3 mRNA expression is not increased as
drastically in comparison with IL-10, as frequent and
large quantity sensitization with M. pneumoniae anti-
gens induced CD4+CD25+T cell translocation from
thymus to the lung.
Additionally, we performed an in vitro analysis aimed to
evaluate the specificity of immuno-inducibility and Th17-
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gens. It was reported that IL-6 and TGF-β1 are
necessary for early differentiation of the Th17 cell from
naïve T cells [38]. Therefore, mouse lymphocytes were
primed with M. pneumoniae antigens in the presence of
IL-6 and TGF-β1. Furthermore, in order to simulate the
presentation of M. pneumoniae antigens by dendritic
cells in vitro, we added anti-CD3 antibodies and anti-
CD28 antibodies.
Compared to saline control, 50 μg protein/ml of M.
pneumoniae antigen stimulation significantly induced
IL-17A production by mouse lymphocytes from day 2 to
5, with greater than sixfold production observed on day
3 (Figure 4a). Additionally, IL-10 production showed a
significant increase from day 1 to 5 (Figure 4b). This
showed that IL-17A and IL-10 production in vitro in-
duced by M. pneumoniae antigen sensitization mirrored
the in vivo antigen induced inflammation model.
When we compared viable cell count at the peak of
IL-17A and IL-10 production on day 4, 50 μg protein/ml
of M. pneumoniae antigens induced multiplication of
mouse lymphocytes approximately twofold compared to
saline control. Though mildly increased growth rates
were observed in the presence of IL-6 and TGF-β1,
higher concentrations of M. pneumoniae antigens in-
duced activation and proliferation of lymphocytes
(Table 1). IL-17A and IL-10 production were enhanced
in a concentration-dependent manner by M. pneumo-
niae antigens, and the presence of IL-6 and TGF-β1 led
to further production of IL-17A and IL-10 (Figures 5a,
6a), showing induction of the two genes under a Th17
dominant immune balance both in vivo and in vitro.
With respect to the effects of antigens prepared from
bacteria causing a classical pneumonia, 50 μg protein/ml
of S. pneumoniae sonicated antigens imposed a lethal
effect on lymphocytes, with decreased viability to 18% of
saline control, possibly through the effect of pneumoly-
sin (Table 1). S. pneumoniae is well known to produce
various virulence factors, and pneumolysin is an intracel-
lular cytotoxin causing lysis of the cytoplasmic membrane
of host cells by perforation [39]. Due to lymphocyte death
and reduction of activity by pneumolysin containing
S. pneumoniae sonicated antigens, IL-17A and IL-10
production was not observed in a concentration-dependent
manner (Figures 5b, 6b).
Regardless of the addition of IL-6 and TGF-β1, 50 μg
protein/ml of K. pneumoniae antigens had a distinct
lethal effect on mouse lymphocytes, with a viability of
approximately 6% at 4 days. Cell death in this expe-
riment was observed in a K. pneumoniae antigen
concentration-dependent manner (Table 1). Recently, it
was reported that K. pneumoniae produced various
lethal active metabolites including cytotoxins, hydrolytic
enzymes and haemolysins similar to S. pneumoniae[40,41] and both IL-17A and IL-10 production were
decreased as expected by exposure to K. pneumoniae anti-
gens (Figures 5c, 6c).
The difference in pathogenic mechanism between
M. pneumoniae and other pulmonary pathogenic bacteria
can be explained by the results of in vitro analyses. The
antigens derived from bacteria causing pneumonia showed
lethality to immunocytes, but M. pneumoniae antigens
lead to activation of host immune responses.
LPS is recognized by TLR 4 and activates macro-
phages [42,43]. However, in this in vitro study, LPS did
not induce proliferation of lymphocytes (Table 1). In
addition, LPS stimulated IL-17A and IL-10 production
did not occur in a concentration-dependent manner
(Figures 5d, 6d). It was considered that in comparison
with M. pneumoniae antigen, LPS has minimal effect
on Th17 cell differentiation.
Zymosan A is recognized by a polymer of TLR2 and
TLR1 or TLR6, causing macrophage activation [44].
Zymosan A induced proliferation of lymphocytes and
IL-10 production in a concentration-dependent man-
ner similar to M. pneumoniae antigens (Table 1,
Figure 6e). However, there was no significant dose-
dependant increase in IL-17A production (Figure 5e) and
so we did not consider Zymosan A to be a major player in
Th17 cell differentiation. Zymosan A induces not only
innate immunity but a Th17 response via Jagged1 acti-
vation on the dendritic cell and was recently reported as
a Th17 adjuvant [45]. From the above, we can conclude
that Zymosan A alone without other immune cells can acti-
vate the proliferation of lymphocytes, but cannot induce a
potent Th17 response even in the presence of IL-6 and
TGF-β1.
Conclusions
In this study, it was shown that M. pneumoniae antigens
induced potent immunoreaction and enhanced the Th17
cell response both in vivo and in vitro, and that both
Treg and IL-10 are involved in the suppression of IL-
17A production. This raises the possibility that break-
down of the immune balance may be part of the process
leading to subsequent development of extrapulmonary
mycoplasmal pneumonia.
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